A contraceptive patch developed by Agile Therapeutics was awarded FDA approval late Friday, clearing the way for a new birth control option to reach the market.
The FDA has placed a clinical hold on a LogicBio Therapeutics application to begin human testing of its experimental gene-editing therapy for a rare, inherited liver disorder.
Two experimental drugs from Eli Lilly and Roche have failed a clinical trial testing them as treatments for a form of Alzheimer’s disease caused by certain genetic mutations, the companies reported Monday.
The study, sponsored by Washington University, tested the drugs... Read more »
Scripps Research is charting new territory with its Calibr division, a drug discovery and drug development group within the research institute that is advancing its own experimental treatments.
Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated.
Beam, which was slated to begin trading Thursday on the Nasdaq exchange under the stock symbol “BEAM,”... Read more »
Last week the FDA approved an Aimmune Therapeutics drug for children with peanut allergies, the first oral immunotherapy for a food allergy to get the agency’s nod.
Verily, the life sciences spinout of Google parent Alphabet, has inked a deal with a Japanese ophthalmology company to develop digital tools and technologies to improve eye health.
Santen Pharmaceutical, which is based in Osaka, has a global industrial and commercial... Read more »
Andreessen Horowitz (a16z), a Silicon Valley venture capital firm best known for backing high-flying software startups such as Facebook, Lyft, and Skype, is doubling down on its foray into biotech-related bets.
A16z on Tuesday revealed it has raised $750 million for... Read more »
Bristol-Myers Squibb is still digesting the commercialized and clinical-stage assets that came with its $74 billion acquisition of Celgene, but the pharmaceutical giant has also been making moves to feed its pipeline with compounds at earlier points of development. An... Read more »
A year ago Passage Bio launched with $115.5 million and plans to advance a handful of gene therapies discovered at the University of Pennsylvania.
Now the Philadelphia-based biotech is preparing to join the public markets and raise millions more to move... Read more »
Rare disease drug developer Insmed on Monday revealed data from a mid-stage trial of its daily pill for adults with non-cystic fibrosis bronchiectasis, a severe chronic pulmonary disorder with no FDA-approved therapies.
Patients with chronic inflammatory lung diseases end up with... Read more »